[go: up one dir, main page]

WO2004021978A3 - Antisense modulation of endothelial specific molecule 1 expression - Google Patents

Antisense modulation of endothelial specific molecule 1 expression Download PDF

Info

Publication number
WO2004021978A3
WO2004021978A3 PCT/US2003/025833 US0325833W WO2004021978A3 WO 2004021978 A3 WO2004021978 A3 WO 2004021978A3 US 0325833 W US0325833 W US 0325833W WO 2004021978 A3 WO2004021978 A3 WO 2004021978A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression
specific molecule
esm
endothelial specific
antisense modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/025833
Other languages
French (fr)
Other versions
WO2004021978A2 (en
Inventor
Edward J Weinstein
David W Griggs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to EP03781285A priority Critical patent/EP1543159A2/en
Priority to JP2004534294A priority patent/JP2006511207A/en
Priority to AU2003288898A priority patent/AU2003288898A1/en
Publication of WO2004021978A2 publication Critical patent/WO2004021978A2/en
Anticipated expiration legal-status Critical
Publication of WO2004021978A3 publication Critical patent/WO2004021978A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antisense compounds, compositions, and methods are provided for modulating the expression of Endothelial Specific Molecule-1 (ESM-1). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ESM-1. Methods of using these compounds for modulation of ESM-1 expression and for treatment of diseases associated with expression of ESM-1 are provided.
PCT/US2003/025833 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression Ceased WO2004021978A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03781285A EP1543159A2 (en) 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression
JP2004534294A JP2006511207A (en) 2002-08-19 2003-08-19 Antisense modulation of endothelium-specific molecule-1 expression
AU2003288898A AU2003288898A1 (en) 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40449502P 2002-08-19 2002-08-19
US60/404,495 2002-08-19

Publications (2)

Publication Number Publication Date
WO2004021978A2 WO2004021978A2 (en) 2004-03-18
WO2004021978A3 true WO2004021978A3 (en) 2005-04-21

Family

ID=31978255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025833 Ceased WO2004021978A2 (en) 2002-08-19 2003-08-19 Antisense modulation of endothelial specific molecule 1 expression

Country Status (4)

Country Link
EP (1) EP1543159A2 (en)
JP (1) JP2006511207A (en)
AU (1) AU2003288898A1 (en)
WO (1) WO2004021978A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006091841A2 (en) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
CA2666657A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
KR101058753B1 (en) 2007-11-22 2011-08-24 한국생명공학연구원 Characterization of ESM-1 as a tumor associated marker of colorectal cancer
JPWO2014112144A1 (en) * 2013-01-15 2017-01-19 国立大学法人 熊本大学 Nucleic acid anticancer agent targeting satellite non-coding RNA derived from chromosome centromere, and method using the anticancer agent
EP2965088B1 (en) * 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
NL2016967B1 (en) * 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
KR102612990B1 (en) * 2020-12-02 2023-12-13 주식회사 에이치피바이오 Rna aptamer specifically binding to esm-1 protein and using the same
CN115154605A (en) * 2022-05-31 2022-10-11 首都医科大学附属北京安贞医院 Use of products for reducing endothelial cell specific molecule-1 levels in preparation of products for treating vascular inflammation or atherosclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258790B1 (en) * 1998-10-05 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of integrin α4 expression
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US6475797B1 (en) * 2000-11-03 2002-11-05 Isis Pharmaceuticals, Inc. Antisense modulation of SR-CYP expression
US6670328B1 (en) * 1997-06-24 2003-12-30 Institut Pasteur De Lille Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670328B1 (en) * 1997-06-24 2003-12-30 Institut Pasteur De Lille Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration
US6258790B1 (en) * 1998-10-05 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of integrin α4 expression
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US6475797B1 (en) * 2000-11-03 2002-11-05 Isis Pharmaceuticals, Inc. Antisense modulation of SR-CYP expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRANCH A.: "A good antisense molecule is hard to find", TIBS, vol. 23, 1998, pages 45 - 50, XP002910401 *
JEN ET AL: "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies", STEM CELLS, vol. 18, 2000, pages 307 - 319, XP002948605 *

Also Published As

Publication number Publication date
JP2006511207A (en) 2006-04-06
WO2004021978A2 (en) 2004-03-18
EP1543159A2 (en) 2005-06-22
AU2003288898A8 (en) 2004-03-29
AU2003288898A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2003048324A3 (en) Antisense modulation of phospholipid scramblase 3 expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
EP1417351A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN EXPRESSION (A)
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2004021978A3 (en) Antisense modulation of endothelial specific molecule 1 expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2004010956A3 (en) Antisense modulation of lar expression
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2004003201A3 (en) Antisense modulation of lrh1 expression
WO2004001061A3 (en) Antisense modulation of heme oxygenase 1 expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003781285

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004534294

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003781285

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003781285

Country of ref document: EP